Christopher Sarchi Sells 3,749 Shares of Replimune Group, Inc. (NASDAQ:REPL) Stock

Replimune Group, Inc. (NASDAQ:REPL) insider Christopher Sarchi sold 3,749 shares of the firm’s stock in a transaction that occurred on Tuesday, May 20th. The stock was sold at an average price of $8.05, for a total transaction of $30,179.45. Following the sale, the insider now owns 128,296 shares in the company, valued at approximately $1,032,782.80. This trade represents a 2.84% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Replimune Group Price Performance

Shares of Replimune Group stock opened at $8.35 on Friday. Replimune Group, Inc. has a twelve month low of $4.92 and a twelve month high of $17.00. The stock has a market capitalization of $643.08 million, a P/E ratio of -2.72 and a beta of 0.68. The company has a current ratio of 11.43, a quick ratio of 11.43 and a debt-to-equity ratio of 0.14. The business’s fifty day moving average price is $8.63 and its 200 day moving average price is $11.21.

Replimune Group (NASDAQ:REPL) last issued its earnings results on Thursday, May 22nd. The company reported ($0.82) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.07). During the same quarter in the previous year, the business posted ($0.25) earnings per share. As a group, research analysts anticipate that Replimune Group, Inc. will post -2.97 earnings per share for the current year.

Institutional Trading of Replimune Group

A number of institutional investors have recently modified their holdings of the company. Optimize Financial Inc acquired a new stake in shares of Replimune Group in the first quarter worth $140,000. Exome Asset Management LLC raised its position in Replimune Group by 438.6% in the first quarter. Exome Asset Management LLC now owns 294,846 shares of the company’s stock valued at $2,875,000 after purchasing an additional 240,108 shares during the period. Goldman Sachs Group Inc. raised its position in Replimune Group by 20.9% in the first quarter. Goldman Sachs Group Inc. now owns 690,167 shares of the company’s stock valued at $6,729,000 after purchasing an additional 119,145 shares during the period. Dynamic Technology Lab Private Ltd purchased a new position in Replimune Group in the first quarter valued at about $343,000. Finally, Parkman Healthcare Partners LLC raised its position in Replimune Group by 9.3% in the first quarter. Parkman Healthcare Partners LLC now owns 950,399 shares of the company’s stock valued at $9,266,000 after purchasing an additional 80,640 shares during the period. Hedge funds and other institutional investors own 92.53% of the company’s stock.

Analyst Ratings Changes

A number of analysts recently issued reports on REPL shares. JPMorgan Chase & Co. raised their target price on shares of Replimune Group from $16.00 to $18.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 26th. HC Wainwright lifted their price objective on Replimune Group from $21.00 to $22.00 and gave the company a “buy” rating in a research report on Thursday, February 13th. Seven investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company has an average rating of “Buy” and an average target price of $19.43.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.